{"id":"mencevax-acw","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Injection site erythema"},{"rate":null,"effect":"Injection site swelling"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL5975302","moleculeType":null,"molecularWeight":"308.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified polysaccharide capsules from meningococcal serogroups A, C, W, and Y conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent immune response. This conjugation approach improves antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against invasive meningococcal disease caused by these serogroups.","oneSentence":"Mencevax ACW is a meningococcal polysaccharide conjugate vaccine that stimulates immune response against Neisseria meningitidis serogroups A, C, W, and Y.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:48.099Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y"}]},"trialDetails":[{"nctId":"NCT00317109","phase":"PHASE3","title":"Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04-19","conditions":"Infections, Meningococcal","enrollment":168}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Mencevax™ ACW","genericName":"Mencevax™ ACW","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Mencevax ACW is a meningococcal polysaccharide conjugate vaccine that stimulates immune response against Neisseria meningitidis serogroups A, C, W, and Y. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}